头孢噻肟-氨基糖苷类联合用药对耐氨基糖苷类铜绿假单胞菌的活性
Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.
作者信息
Murray P R
出版信息
Antimicrob Agents Chemother. 1980 Mar;17(3):474-6. doi: 10.1128/AAC.17.3.474.
Abstract
The activity of cefotaxime, either alone or combined with an aminoglycoside, was determined against 50 isolates of Pseudomonas aeruginosa, of which 50, 33, and 10 were resistant to gentamicin, tobramycin, and amikacin, respectively. Cefotaxime inhibited 34 isolates at a concentration of 16 microgram/ml and all isolates at 128 microgram/ml. The combinations of cefotaxime with gentamicin, tobramycin, and amikacin were synergistic against 30, 17, and 9 isolates, respectively, and no antagonism was observed with any combination. Synergism was obtained at clinically significant antibiotic concentrations for nine isolates with cefotaxime-gentamicin, five isolates with cefotaxime-tobramycin, and nine isolates with cefotaxime-amikacin.
摘要
测定了头孢噻肟单独使用或与一种氨基糖苷类药物联合使用时对50株铜绿假单胞菌的活性，其中分别有50株、33株和10株对庆大霉素、妥布霉素和阿米卡星耐药。头孢噻肟在浓度为16微克/毫升时抑制了34株菌株，在128微克/毫升时抑制了所有菌株。头孢噻肟与庆大霉素、妥布霉素和阿米卡星的联合用药分别对30株、17株和9株菌株具有协同作用，且未观察到任何联合用药有拮抗作用。对于9株使用头孢噻肟-庆大霉素联合用药的菌株、5株使用头孢噻肟-妥布霉素联合用药的菌株和9株使用头孢噻肟-阿米卡星联合用药的菌株，在具有临床意义的抗生素浓度下获得了协同作用。
相似文献
1
Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.头孢噻肟-氨基糖苷类联合用药对耐氨基糖苷类铜绿假单胞菌的活性
Antimicrob Agents Chemother. 1980 Mar;17(3):474-6. doi: 10.1128/AAC.17.3.474.
2
In vitro activity of ceftriaxone alone and in combination with gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.头孢曲松单独及与庆大霉素、妥布霉素和阿米卡星联合应用对铜绿假单胞菌的体外活性。
Antimicrob Agents Chemother. 1983 Aug;24(2):305-6. doi: 10.1128/AAC.24.2.305.
3
Global and effective synergism of amikacin, gentamicin or tobramycin when combined with carbenicillin against Pseudomonas aeruginosa.阿米卡星、庆大霉素或妥布霉素与羧苄西林联合使用时对铜绿假单胞菌具有全面且有效的协同作用。
J Int Med Res. 1979;7(5):375-8. doi: 10.1177/030006057900700507.
4
In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.头孢曲松与氨基糖苷类药物对铜绿假单胞菌的体外及体内协同作用。
Eur J Clin Microbiol. 1983 Oct;2(5):489-95. doi: 10.1007/BF02013914.
5
Comparative activity of netilmicin, gentamicin, amikacin, and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae.奈替米星、庆大霉素、阿米卡星和妥布霉素对铜绿假单胞菌和肠杆菌科细菌的比较活性。
Antimicrob Agents Chemother. 1976 Oct;10(4):592-7. doi: 10.1128/AAC.10.4.592.
6
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.氨基糖苷类药物与β-内酰胺类药物联合用于抗革兰氏阴性菌。体外协同作用及化学相互作用的评估。
Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0.
7
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.妥布霉素、阿米卡星和庆大霉素单独及与羧苄西林联合使用对铜绿假单胞菌的比较活性
Antimicrob Agents Chemother. 1974 Oct;6(4):442-6. doi: 10.1128/AAC.6.4.442.
8
9
[Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)].四种氨基糖苷类抗生素（阿米卡星、庆大霉素、卡那霉素和妥布霉素）杀菌效果的比较（作者译）
Ann Microbiol (Paris). 1979 Apr;130A(3):331-43.
10
Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa.新型氨基糖苷类抗生素和羧苄青霉素单独及联合使用时对庆大霉素耐药铜绿假单胞菌的活性。
Antimicrob Agents Chemother. 1976 Sep;10(3):399-401. doi: 10.1128/AAC.10.3.399.
引用本文的文献
1
Uncovering the Important Genetic Factors for Growth during Cefotaxime-Gentamicin Combination Treatment in Encoding .揭示头孢噻肟-庆大霉素联合治疗编码过程中生长的重要遗传因素。
Antibiotics (Basel). 2023 Jun 1;12(6):993. doi: 10.3390/antibiotics12060993.
2
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.头孢噻肟。对其抗菌活性和药代动力学特性的重新评估，以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.
3
In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.头孢曲松与氨基糖苷类药物对铜绿假单胞菌的体外及体内协同作用。
Eur J Clin Microbiol. 1983 Oct;2(5):489-95. doi: 10.1007/BF02013914.
4
Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.头孢噻肟：抗菌活性、药理特性及治疗用途综述
Drugs. 1983 Mar;25(3):223-89. doi: 10.2165/00003495-198325030-00001.
5
Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.氨曲南及头孢噻肟单用或联用妥布霉素对铜绿假单胞菌和金黄色葡萄球菌的血清杀菌活性
Antimicrob Agents Chemother. 1981 Oct;20(4):539-41. doi: 10.1128/AAC.20.4.539.
6
Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.头孢噻肟治疗下呼吸道感染的临床评估。
Antimicrob Agents Chemother. 1982 Feb;21(2):327-33. doi: 10.1128/AAC.21.2.327.
7
Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.
Infection. 1985;13 Suppl 1:S28-33. doi: 10.1007/BF01644214.
8
Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.头孢噻肟联合阿米卡星作为经验性治疗用于血液系统恶性肿瘤中性粒细胞减少患者发热性疾病的治疗。
Infection. 1985 May-Jun;13(3):125-9. doi: 10.1007/BF01642871.
本文引用的文献
1
Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.癌症患者的经验性治疗：替卡西林-妥布霉素、替卡西林-头孢噻吩和头孢噻吩-妥布霉素的对比研究。
Antimicrob Agents Chemother. 1975 May;7(5):640-5. doi: 10.1128/AAC.7.5.640.
2
Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole.HR756与头孢噻吩、头孢西丁和头孢孟多的体外活性比较。
Antimicrob Agents Chemother. 1978 Dec;14(6):876-9. doi: 10.1128/AAC.14.6.876.
3
HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.HR 756，一种对革兰氏阳性菌及革兰氏阴性需氧菌和厌氧菌均有活性的新型头孢菌素。
Antimicrob Agents Chemother. 1979 Feb;15(2):273-81. doi: 10.1128/AAC.15.2.273.
4
Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.HR 756对流感嗜血杆菌、脆弱拟杆菌和革兰氏阴性杆菌的活性。
J Antimicrob Chemother. 1978 Sep;4(5):445-50. doi: 10.1093/jac/4.5.445.
5
Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.头孢噻肟（HR 756）是一种新型头孢菌素，在体外具有卓越的广谱活性。
J Antimicrob Chemother. 1978 Sep;4(5):437-44. doi: 10.1093/jac/4.5.437.
6
In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae.新型头孢菌素HR 756对淋病奈瑟菌的体外活性
Antimicrob Agents Chemother. 1979 Mar;15(3):452-4. doi: 10.1128/AAC.15.3.452.
7
In vitro activity of HR 756, a new cephalosporin compound.新型头孢菌素化合物HR 756的体外活性
J Antibiot (Tokyo). 1978 Nov;31(11):1170-4. doi: 10.7164/antibiotics.31.1170.
8
Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.哌拉西林、替卡西林或羧苄西林与氨基糖苷类抗生素之间相互作用的分析。
Antimicrob Agents Chemother. 1978 Sep;14(3):505-6. doi: 10.1128/AAC.14.3.505.
9
Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.头孢噻吩加一种氨基糖苷类药物比甲氧西林加一种氨基糖苷类药物的肾毒性更大。
Lancet. 1978 Sep 16;2(8090):604-6. doi: 10.1016/s0140-6736(78)92825-8.
Zotero 插件